Share
Media and tech aren’t just intersecting — they’re fully intertwined. And to understand how those worlds work, and what they mean for you, veteran journalist Peter Kafka talks to industry leaders, upstarts and observers - and gets them to spell it out in plain, BS-free English. Part of the Vox Media Podcast Network.
…
continue reading
Manage episode 491180705 series 3386301
Content provided by Questex Podcasts and Fierce Life Sciences. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Questex Podcasts and Fierce Life Sciences or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://staging.podcastplayer.com/legal.
Two and a half years into his tenure as Teva’s CEO, Richard Francis is breaking down the strategy that’s powered the company through nine consecutive quarters of growth.
On this week’s episode of "The Top Line," Fierce Pharma’s Fraiser Kansteiner sits down with Francis to talk about the progress made so far on Teva’s “Pivot to Growth” strategy and what comes next. They dig into the strategies behind the company’s chief commercial medicines, its pipeline darlings and the way Teva’s generic and biosimilar backbone is expected to evolve through the end of the decade.
To learn more about the topics in this episode:
- As Austedo, Ajovy and Uzedy gain steam, Teva banks on $5B-plus in 2030 innovative drug sales
- Teva plots thousands of job cuts as restructuring drive enters 'acceleration' phase
- Teva taps Matthew Shields to oversee manufacturing and supply division amid company revamp
This week's episode is sponsored by Cencora.
See omnystudio.com/listener for privacy information.
101 episodes
))
